千金药业: 千金药业关于限制性股票回购注销实施公告

Core Viewpoint - The company, Zhuzhou Qianjin Pharmaceutical Co., Ltd., is implementing a repurchase and cancellation of restricted stock due to the failure to meet performance conditions for the second and third unlock periods of its 2021 restricted stock incentive plan [1][2]. Group 1: Repurchase and Cancellation Details - The repurchase involves a total of 5,490,000 shares of restricted stock, which will be canceled following the failure to meet the performance criteria set for the second and third unlock periods [2][4]. - The decision for the repurchase was approved by the 11th Supervisory Board meeting and does not require further approval from the shareholders' meeting [1][2]. - The company has established a dedicated securities account for the repurchase at the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, with the cancellation expected to be completed by July 10, 2025 [4][5]. Group 2: Impact on Share Structure - Following the repurchase and cancellation, the company's share structure will change as follows: - Restricted shares before: 5,490,000; after: 0 - Unrestricted shares before: 418,507,117; after: 418,507,117 - Total shares before: 423,997,117; after: 418,507,117 [5]. Group 3: Compliance and Legal Opinions - The company assures that the decision-making process and information disclosure comply with relevant laws and regulations, including the Management Measures for Equity Incentives of Listed Companies [4][5]. - The legal opinion from Hunan Qiyuan Law Firm confirms that the repurchase and cancellation comply with applicable laws and regulations, and the company will fulfill its information disclosure obligations [5][6].